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AbstrAct
Bone marrow mesenchymal stem cells (MSCs) are an important participant in 
the tumor microenvironment, in which they promote tumor growth and progression. 
Here we report for the first time that depletion of lysosomal acid lipase (LAL) in MSCs 
impairs their abilities to stimulate tumor growth and metastasis both in allogeneic and 
syngeneic mouse models. Reduced cell viability was observed in LAL-deficient (lal−/−) 
MSCs, which was a result of both increased apoptosis and decreased proliferation due 
to cell cycle arrest. The synthesis and secretion of cytokines and chemokines that 
are known to mediate MSCs’ tumor-stimulating and immunosuppressive effects, i.e., 
IL-6, MCP-1 and IL-10, were down-regulated in lal−/− MSCs. When tumor cells were 
treated with the conditioned medium from lal−/− MSCs, decreased proliferation was 
observed, accompanied by reduced activation of oncogenic intracellular signaling 
molecules in tumor cells. Co-injection of lal−/− MSCs and B16 melanoma cells into wild 
type mice not only induced CD8+ cytotoxic T cells, but also decreased accumulation 
of tumor-promoting Ly6G+CD11b+ myeloid-derived suppressor cells (MDSCs), which 
may synergistically contribute to the impairment of tumor progression. Furthermore, 
lal−/− MSCs showed impaired differentiation towards tumor-associated fibroblasts. 
In addition, MDSCs facilitated MSC proliferation, which was mediated by MDSC-
secreted cytokines and chemokines. Our results indicate that LAL plays a critical role 
in regulating MSCs’ ability to stimulate tumor growth and metastasis, which provides 
a mechanistic basis for targeting LAL in MSCs to reduce the risk of cancer metastasis. 
IntroductIon
Tumor progression and metastasis are 
greatly influenced by non-malignant cells in the 
microenvironment. Many of these cells are derived from 
the bone marrow, and recruited by cancer cells to enhance 
their survival, growth, invasion and dissemination [1]. 
Mesenchymal stem cells (MSCs) are non-hematopoietic 
stem cells residing in the bone marrow that have the ability 
to self-renew and differentiate into multiple lineages, 
which contribute to tissue homeostasis and regeneration 
[2]. Recently, numerous studies have shown that bone 
marrow-derived MSCs participate in tumor progression 
by establishing a favorable tumor microenvironment 
[3–6]. MSCs not only support the tumor vasculature by 
differentiating into pericytes and perhaps endothelial 
cells, and secreting vasculogenic growth factors [6], 
but also differentiate into tumor-associated fibroblasts 
(TAFs), which establish cytokine networks that promote 
progression and migration [7]. In addition, MSCs display 
immunomodulatory properties by inhibiting proliferation 
and function of several major immune cells [8], which 
might be an important mechanism through which 
MSCs promote tumor growth or increase incidence of 
tumor formation.
Lysosomal acid lipase (LAL) is a key enzyme in 
the metabolic pathway of neutral lipids, which hydrolyzes 
cholesteryl esters and triglycerides in the lysosome of 
cells to generate free fatty acids and cholesterol. Genetic 
ablation of the lal gene in mice has profound pathogenic 
effects in multiple organs including myelopoiesis [9–11]. 
The effects of LAL deficiency on several types of cells, 
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including aberrant growth and differentiation of myeloid 
lineage cells [11], impaired development and function of 
T cells [12], and abnormal proliferation and dysfunctions 
of endothelial cells [13] have been reported. However, the 
effect of LAL deficiency in MSCs is still unknown.
In the present study, the ability of LAL-deficient 
(lal−/−) MSCs in promoting tumor growth and metastasis 
was determined. The underlying mechanisms through 
which LAL deficiency affects MSC tumor-promoting 
functions were further investigated, including the effect 
of LAL deficiency on the MSC proliferation potential, 
synthesis and secretion of tumor-promoting cytokines 
and chemokines, lal−/− MSCs-induced changes of immune 
cells, and MSCs’ differentiation towards TAFs. In addition, 
the relationship between myeloid-derived suppressor 
cells (MDSCs) and MSCs was examined. Our study 
demonstrates that LAL deficiency in MSCs impairs their 
stimulation of tumor growth and metastasis by restricting 
MSC proliferation, reducing synthesis and secretion 
of tumor-promoting cytokines/chemokines, inducing 
CD8+ T lymphocytes and decreasing accumulation of 
MDSCs, and impairing differentiation towards TAFs. 
These findings provide a mechanistic insight into LAL in 
controlling MSCs’ tumor-promoting functions. Melanoma 
B16 cell line and LLC lung cancer cell line were used for 
the investigation. Melanoma is a popular cancer form and 
a perfect model for easy detection of metastasis without 
extensive pathological dissection and characterization. 
Lung cancer is the leading cause of cancer deaths, 
accounting for approximately 27% of all cancer deaths. 
results
lAl is required for Mscs’ stimulation of tumor 
cell growth and metastasis
Numerous studies have shown that MSCs are 
involved in tumor progression and metastasis, during 
which they exert stimulatory effects [6]. To see whether 
LAL plays a role in regulating MSCs’ effect on tumor 
progression, the B16 melanoma cell model was used for 
subcutaneous and intravenous co-injection with bone 
marrow MSCs in both syngeneic C57BL/6 and allogeneic 
FVB/N mouse models. To examine the tumor growth 
potential in vivo, MSCs from C57BL/6 or FVB/N mice 
were mixed with B16 melanoma cells, and then co-
injected subcutaneously into wild-type (lal+/+) C57BL/6 
or FVB/N mice, respectively. B16 melanoma tumor 
grew faster in C57BL/6 syngeneic background than that 
in allogenic FVB/N background (Figure 1A and 1B). 
Compared with tumor growth in lal+/+ mice given only 
melanoma cells, both lal+/+ and lal−/− MSCs facilitated 
tumor growth (Figure 1A and 1B). However, the tumors 
from lal−/− MSCs-injected mice were significantly smaller 
than those developed in lal+/+ MSCs-injected mice at 7, 
14, 21 and 28 days post-injection in both allogeneic and 
syngeneic conditions. Therefore, LAL deficiency in MSCs 
impaired their tumor growth stimulation effect. 
Next, MSCs from C57BL/6 or FVB/N mice mixed 
with B16 melanoma cells were co-injected into the tail 
veins of lal+/+ C57BL/6 or FVB/N mice, respectively, to 
detect the metastatic potential. Two weeks after injection, 
compared to the lal+/+ C57BL/6 syngeneic mice that 
received melanoma cells only, the lal+/+ C57BL/6 mice 
co-injected with lal+/+ MSCs developed more melanoma 
colonies in the lungs (Figure 1D). In comparison, less B16 
melanoma colonies were observed in the lungs of lal+/+ 
C57BL/6 syngeneic mice that received lal−/− MSCs than 
those received lal+/+ MSCs under the syngeneic condition 
(Figure 1D). In allogeneic recipient FVB/N lal+/+ mice, 
melanoma metastasized less effectively due to immune 
rejection compared to syngeneic recipient C57BL/6 lal+/+ 
mice. Furthermore, co-injection of lal−/− MSCs completely 
wiped out melanoma colonization in the lungs of lal+/+ 
FVB/N mice (Figure 1C). The above data suggested that 
LAL deficiency suppresses MSCs’ stimulation of tumor 
growth and metastasis. To further investigate whether 
MSCs exist in the metastatic sites, CMFDA-labeled MSCs 
from lal+/+ and lal−/− mice were intravenously co-injected 
with B16 melanoma cells into the allogeneic FVB/N lal+/+ 
mice. Sixteen hours later, the mice were sacrificed and the 
lung, spleen and blood were harvested for flow cytometry 
analysis of the existence of MSCs. As shown in Figure 1E, 
labeled MSCs were found in the lungs of both lal−/− MSC-
injected and lal+/+ MSC-injected mice, but not in the spleen 
and blood. In consistent with this finding, no metastasis was 
observed in other organs within the investigated period.
lAl is required for Msc proliferation
LAL is known to influence cell proliferation in 
several cell types in lal−/− mice [13, 14]. To assess the 
LAL influence on MSC proliferation, a cell growth curve 
assay was performed. As shown in Figure 2A, LAL 
deficiency decreased MSC proliferation in comparison to 
lal+/+ MSCs. This result was further confirmed by BrdU 
incorporation assay (Figure 2B). Consistent with growth 
arrest, LAL deficiency led to decreased expression of cell 
cycle-related genes, such as cyclin A (required for both 
S-phase progression and G2/M-phase transition), cyclin B 
(required for mitosis), cyclin E (required for G1/S-phase 
transition), and cyclin-dependent kinase (CDK) 1 and 2 
(Figure 2C). The above data demonstrated that LAL is 
required for MSC proliferation. 
The decreased cell viability in lal−/− MSCs can 
occur as a result of either decreased proliferation, or 
increased apoptosis. Annexin V staining was performed 
to evaluate the apoptotic activity in lal−/− vs. lal+/+ MSCs. 
As shown in Figure 2D, the percentage of Annexin V+ 
cells in lal−/− MSCs was significantly greater than in lal+/+ 
MSCs, indicating increased apoptosis in lal−/− MSCs. We 
further compared the caspase 3 activity between lal+/+ 
and lal−/− MSCs. The result revealed that lal−/− MSCs 
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Figure 1: lAl is required for Mscs’ stimulation of tumor cell growth and metastasis. (A) Statistical analysis of tumor 
volume (in cubic millimeters) at 7, 14, 21 and 28d post-injection in FVB/N mice. MSCs (6 × 105) from lal+/+ or lal−/− FVB/N mice and B16 
melanoma cells (2 × 105) were mixed, and then injected subcutaneously into the flank region of 3-month old lal+/+ FVB/N mice. Data were 
expressed as mean ± SD; n = 6~10. **P < 0.01 vs. lal−/− MSCs. (b) Statistical analysis of tumor volume at 7, 14, 21 and 28d post-injection 
in C57BL/6 mice. The experimental condition was the same in (A). Data were expressed as mean ± SD; n = 3~6. *P < 0.05, **P < 0.01 vs. 
lal−/− MSCs. (c) Quantitative analysis of the melanoma colony numbers in the lungs of FVB/N mice. MSCs (8 × 105) from lal+/+ or lal−/− 
FVB/N mice and B16 melanoma cells (4 × 105) were intravenously injected into lal+/+ FVB/N mice for 2 weeks. Representative lungs are 
shown. Data were expressed as mean ± SD; n = 9 ~ 10. **P < 0.01. (d) Quantitative analysis of the melanoma colony numbers in the lungs 
of lal+/+ C57BL/6 mice. The experimental condition was the same in (C). Representative lungs are shown. Data were expressed as mean ± 
SD; n = 5 ~ 6. *P < 0.05, **P < 0.01. (e) Flow cytometry analysis of MSCs in the lung, spleen and blood of FVB/N mice. CMFDA-labeled 
lal+/+ or lal−/− FVB/N MSCs (1 × 106) were intravenously co-injected with B16 melanoma cells (5 × 105) into FVB/N lal+/+ mice. Sixteen 
hours later, the mice were sacrificed and single cells from the lung, spleen and blood were harvested for flow cytometry analysis of the 
existence of MSCs. Representative pictures are shown. n = 4.
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possessed higher caspase 3 activity than that of lal+/+ 
MSCs (Figure 2E), which was consistent with Annexin V 
staining. Accordingly, the expression of genes involved in 
pro-apoptosis was up-regulated in lal−/− MSCs, including 
caspase 3, 6, 7, 8 and 9, BAX, BAK, BID, and APAF1 
(Figure 2F). Taken together, these data suggested that 
LAL deficiency in MSCs restricts their proliferation by 
modulating cell cycle regulators and inducing cell death.
LAL deficiency reduces synthesis and secretion 
of tumor-promoting cytokines and chemokines 
in Mscs
MSCs have been reported to secrete a variety 
of cytokines and chemokines to influence tumor 
proliferation and migration [6]. In order to determine 
whether LAL deficiency in MSCs affects their secretion of 
Figure 2: lAl is required for Msc proliferation. (A) lal+/+ and lal−/− MSCs growth at d1, d3, d5 and d7. MSCs were seeded at a 
density of 5 × 104 cells/well in 6 well plates on day 0. On day 1, 3, 5, and 7, MSCs were trypsinized and counted with a hemocytometer. 
The cell growth curve was then established by a graphical analysis of the data. (b) The percentage of BrdU incorporation into lal+/+ or 
lal−/− MSCs by flow cytometry. For both (A) and (B), data were expressed as mean ± SD; n = 5. **P < 0.01. (c) Real-time PCR analysis of 
mRNA expression levels of cell cycle-related molecules in lal+/+ vs. lal−/− MSCs. (d) The percentage of Annexin V+ cells in lal+/+ or lal−/− 
MSCs by flow cytometry analyses. Data were expressed as mean ± SD; n = 4. **P < 0.01. (e) The caspase 3 activity in lal+/+ or lal−/− MSCs. 
Data were normalized to lal+/+ MSCs and expressed as mean ± SD; n = 5. **P < 0.01. (F) Real-time PCR analysis of mRNA expression 
levels of apoptosis-related molecules in lal+/+ vs. lal−/− MSCs. For both (C) and (F), the relative gene expression was normalized to GAPDH 
mRNA, and analysis was performed by the 2−ΔΔCT method. Data were expressed as mean ± SD; n = 4. *P < 0.05, **P < 0.01. 
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tumor-facilitating cytokines/chemokines, conditioned 
medium (CM) of MSCs after 3-days culture was harvested. 
Then cytokines and chemokines that are known to promote 
tumorigenesis were measured by ELISA in MSCs isolated 
from both syngeneic and allogeneic mice. For MSCs derived 
from FVB/N mice, the concentrations of IL-6, MCP-1, and 
IL-10 were lower in lal−/− MSC-CM compared with those 
in lal+/+ MSC-CM among tested cytokines and chemokines 
(Figure 3A). Similar results were observed in MSCs derived 
from C57BL/6 mice, except that there was no significant 
change in the MCP-1 level (Figure 3B). This observation 
has been confirmed at the mRNA level from FVB/N MSCs 
(Figure 3C). Therefore, reduced synthesis and secretion of 
IL-6, MCP-1, and IL-10 were, at least in part, responsible 
for the decreased stimulation of tumor growth and metastasis 
by lal−/− MSCs, which formulate a unique signature for 
lal−/− MSCs. We have also examined the levels of M-CSF, 
GM-CSF, G-CSF, IL-1β, TNFα and CCL-5 by ELISA, and 
VEGF and TGF-β by real-time PCR assay, which showed no 
significant changes (data not shown). 
Msc-cM stimulates proliferation of tumor 
cells by up-regulating activation of intracellular 
signaling molecules
To further confirm that MSC-CM is responsible for 
the decreased stimulation of tumor growth and metastasis 
by lal−/− MSCs, tumor cells were treated with lal+/+ or lal−/− 
MSC-CM, and their in vitro proliferation was examined. 
As shown in Figure 4A (left panel), compared with the 
lal+/+ MSC-CM treatment, both FVB/N and C57BL/6 
lal−/− MSC-CM showed a lower stimulatory effect on 
proliferation of B16 melanoma cells after 3 days. A 
similar defect was observed when lal−/− MSC-CM was 
added to LLC cells (Figure 4A, right panel). To further 
investigate whether lal−/− MSC-CM activates oncogenic 
intracellular signaling, a hallmark of tumor proliferation, 
tumor cells were treated with lal+/+ and lal−/− MSC-CM, 
and intracellularly stained with anti-phospho-AKT, anti-
phospho-ERK1/2, anti-phospho-NF-κB, anti-phospho-
STAT3, or anti-phospho-P38 antibodies. Flow cytometry 
analyses revealed that the lal−/− MSC-CM treatment 
showed lower activation of ERK1/2, STAT3, and P38 
in B16 melanoma cells compared with that in lal+/+ 
MSC-CM-treated B16 cells in syngeneic C57BL/6 mice 
(Figure 4B). Similarly, activation of these oncogenic 
intracellular signaling molecules was also reduced in LLC 
cells with lal−/− MSC-CM treatment (Figure 4B). The 
same observation was also made in allogeneic FVB/N 
mice, except activation of P38. We have reported that 
persistent activation of the STAT3 signaling pathway 
induced adenocarcinoma formation in the lung, and 
STAT3 serves as a biomarker for lung adenocarcinoma 
[15, 16]. Therefore, MSCs stimulate proliferation of tumor 
cells by CM through regulating activation of oncogenic 
intracellular signaling molecules. 
lal−/− Mscs restore cd8+ T lymphocytes and 
decrease accumulation of Ly6G+cd11b+ Mdscs
CD8+ T lymphocytes are a very important immune 
population involved in attacking tumor cells. MSCs 
have been reported to provide an immunosuppressive 
environment for tumor growth [17]. To investigate 
whether and how LAL deficiency influences MSCs’ 
ability in immunosuppression of T cells, MSCs and B16 
melanoma cells were co-injected intravenously into lal+/+ 
FVB/N mice. The blood, lung and spleen were harvested 
7 days later for flow cytometry analysis to determine 
the levels of CD4+ and CD8+ T cells. As Figure 5A 
demonstrated, mice injected with lal+/+ MSCs plus B16 
melanoma cells systemically suppressed the CD8+ T cell 
population in the blood, lung and spleen. Mice injected 
with lal−/− MSCs restored CD8+ T cell number back to the 
control level, or even higher. We did not observe the CD8+ 
T cell number difference between B16 tumor cell-injected 
and non-injected mice in these organs. No significant 
change in CD4+ T cells was observed in the blood, lung, 
and spleen of mice injected with lal−/− vs. lal+/+ MSCs plus 
B16 melanoma cells (Figure 5B). 
MDSCs are the well-known immune population that 
suppresses CD8+ T cells. Interestingly, the percentages of 
Ly6G+CD11b+ MDSCs were lower in the blood and lung of 
lal−/− MSCs-injected mice, but not in the spleen compared 
with mice injected with lal+/+ MSCs (Figure 5C). These 
observations suggested that the impaired stimulation of 
tumor growth and metastasis by lal−/− MSCs can be a 
result of restoration of the anti-tumor immunity. 
LAL deficiency impairs MSC differentiation 
towards tAFs
TAFs have been reported to promote tumorigenesis 
in multiple tumor models, and MSCs have been found 
to express TAF antigens after exposure to the tumor 
microenvironment [6]. To see whether LAL deficiency 
influences MSCs’ differentiation towards TAFs in vitro, 
MSCs were treated with the conditioned medium (CM) of 
B16 melanoma cells for 2 weeks. The expression of TAF 
markers was then examined by real-time PCR assay. As 
Figure 6A demonstrated, B16 CM treatment up-regulated 
the gene expression of TAF markers α-smooth muscle 
actin (α-SMA), tenascin-C (Tn-C), and fibroblast marker 
collagen I in lal+/+ MSCs. Although the gene expression 
of Tn-C and collagen I was also increased in lal−/− MSCs, 
their levels were significantly lower than those in lal+/+ 
MSCs, suggesting that LAL deficiency impaired MSCs’ 
differentiation into fibroblasts/myofibroblasts in vitro. 
For their in vivo differentiation, MSCs were mixed 
with B16 melanoma cells in matrigel, and then injected 
subcutaneously into lal+/+ mice. The matrigel plugs were 
harvested 2 weeks later for immunohistochemical staining 
against TAF markers, including α-SMA and desmin. 
Oncotarget61126www.impactjournals.com/oncotarget
In the plugs containing MSCs only, very few cells were 
positive for α-SMA or desmin, and there was no difference 
between lal+/+ and lal−/− MSCs (Figure 6B). However, once 
the MSCs were within the tumor microenvironment, the 
expression of α-SMA and desmin was evident, with more 
positive cells in the plugs containing lal+/+ MSCs and B16 
melanoma cells than those containing lal−/− MSCs and 
B16 cells (Figure 6B). Taken together, LAL deficiency 
impairs MSC differentiation towards TAFs to support 
tumor growth.
MDSCs partially restore decreased proliferation 
of lal−/− Mscs
In the bone marrow, the GR1+CD11b+ MDSCs 
population constitutes approximately 50% of total cells 
in lal+/+ mice and 70% of total cells in lal−/− mice as we 
reported previously [11]. Considering that both MSCs and 
MDSCs originate from the bone marrow, it is necessary to 
examine the effect of MDSCs on MSC proliferation. MSCs 
were co-cultured with or without lal+/+ or lal−/− MDSCs for 
Figure 3: LAL deficiency reduced synthesis and secretion of tumor-promoting cytokines and chemokines in MSCs. 
(A) The secretions of IL-6, MCP-1, and IL-10 in lal+/+ or lal−/− FVB/N MSCs’ conditioned medium by ELISA analysis. MSCs were seeded 
at a density of 5 × 105 cells/well in 6-well plates. Three days later, the conditioned medium was harvested for ELISA analysis. (b) The 
secretions of IL-6, MCP-1, and IL-10 of lal+/+ or lal−/− C57BL/6 MSCs’ conditioned medium by ELISA analysis. For both (A) and (B), data 
were expressed as mean ± SD; n = 4. *P < 0.05. (c) Real-time PCR analysis of mRNA expression levels of IL-6, MCP-1, and IL-10 in 
lal+/+ vs. lal−/− MSCs from FVB/N mice. The relative gene expression was normalized to GAPDH mRNA, and analysis was performed by 
the 2−ΔΔCT method. Data were expressed as mean ± SD; n = 4. *P < 0.05. 
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7 days. As shown in Figure 7A, MSC co-cultured with 
lal−/− MDSCs showed increased proliferation than those 
with lal+/+ MDSCs. Even the decreased proliferation of 
lal−/− MSCs was partially restored after co-culture with 
MDSCs, especially with lal−/− MDSCs. lal−/− MDSCs have 
been reported to exert their effects by secreting cytokines 
[13, 18]. To examine whether cytokines secreted by lal−/− 
MDSCs facilitate MSC proliferation, a transwell study 
was performed with MDSCs seeding in the upper chamber 
and MSCs in the lower chamber. After 5 days’ co-culture, 
the number of MSCs that were co-cultured with lal−/− 
MDSCs was significantly increased (Figure 7B). When 
MDSCs were treated with anti-IL-6, IL-1β, TNFα or 
MCP-1 antibodies to neutralize cytokines in the transwell 
study, the stimulatory effect on MSCs proliferation was 
significantly inhibited by anti-TNFα antibody in both lal+/+ 
MDSCs and lal−/− MDSCs groups (Figure 7C). Inhibition 
by IL-1β antibody was also observed in the lal+/+ MDSCs 
group, but not in the lal−/− MDSCs group. Therefore, 
cytokines (especially TNFα) secreted by MDSCs were, at 
least in part, responsible for mediating stimulatory effects 
on MSC proliferation. 
dIscussIon
MSCs display the ability to modulate the tumor 
microenvironment, thus having an impact on tumor 
growth, progression and metastasis. Here we used 
B16 melanoma cells as a model to compare the tumor-
promoting ability between lal+/+ and lal−/− MSCs, and to 
investigate the underlying mechanisms involved in the 
process. The present study shows for the first time that 
MSCs with LAL deficiency lose the ability to stimulate 
tumor growth and metastasis. 
It has been reported that B16 melanoma cells did 
not form tumors in allogeneic mice unless MSCs were 
co-injected [17]. In our case, although small tumors were 
observed in allogeneic FVB/N mice with B16 melanoma 
cell injection, when B16 melanoma cells were mixed 
with lal+/+ MSCs, their ability to grow and migrate was 
significantly enhanced (Figure 1A and 1C). However, 
LAL deficiency greatly reduced this ability of MSCs in 
the allogeneic FVB/N mouse model. It is interesting that 
lal−/− MSCs almost completely inhibited B16 metastasis 
(Figure 1C). 
Many mechanisms have been proposed to account 
for MSC-mediated effects of tumor support [6]. During 
the process of MSC-mediated tumor growth, MSCs 
need to maintain certain cell viability to perform their 
functions. As we reported before, LAL plays differential 
roles to determine the cell fate in different cell types. 
LAL deficiency promotes proliferation and inhibits 
apoptosis of myeloid lineage cells and endothelial cells 
[13, 19]. In an opposite effect, LAL deficiency inhibits 
proliferation and induces apoptosis of T lymphocytes 
[12]. Similar to T lymphocytes, here we report that the 
decreased cell viability of lal−/− MSCs was observed 
during in vitro culture experiments. Concomitantly, a 
higher caspase 3 activity was observed in lal−/− MSCs 
than that in lal+/+ MSCs, accompanied by up-regulated 
expression of the caspase family members and the pro-
apoptotic genes (Figure 2). Klopp et al. suggested that the 
increased tumor mass observed when MSCs and tumor 
cells were co-injected can be related to the increased 
proliferation of MSCs in tumors [6], indicating that MSC 
proliferation is critical to tumor growth. Funes et al. 
reported that restoration of Nrf2 function in transformed 
MSCs impaired in vivo tumor growth by mechanisms that 
included MSC sensitization to apoptosis [20], suggesting 
that MSC apoptosis is one of the reasons for the impaired 
tumor growth. Therefore, the decreased proliferation and 
increased apoptosis provide a mechanism by which lal−/− 
MSCs lose their viability and ability to stimulate tumor 
growth and metastasis. 
Other mechanisms also play important roles in 
MSCs to stimulate tumor growth. MSCs secrete a variety 
of growth factors, cytokines and chemokines to influence 
tumor proliferation, migration, and angiogenesis [6]. 
Reduced synthesis and secretion of IL-6, MCP-1 and 
IL- 10 were observed in lal−/− MSCs (Figure 3). MSC-
secreted IL-6 has been found to act as a paracrine factor 
to sustain breast cancer cell migration [21]. Besides its 
effects on tumor cells, MSCs themselves are also the target 
of IL-6. Under the influence of IL-6, MSCs can transform 
malignant cells and have tumorigenic properties [22]. 
In addition, IL-6 maintains MSC stemness by enhancing 
proliferation and protecting from apoptosis. Such 
stemness-maintaining effects by IL-6 support our findings 
of the decreased proliferation and increased apoptosis in 
lal−/− MSCs (Figure 2). MCP-1 was reported to facilitate 
breast-tumor metastasis by recruiting inflammatory 
monocytes [23]. IL-10 permits malignant cells escaping 
from cell-mediated immune defenses, and is associated 
with poor prognosis in colon cancer [24]. Moreover, IL-
6, MCP-1 and IL-10 are related to the immunoregulatory 
effects of MSCs [25]. When B16 melanoma or LLC cells 
were treated with conditioned medium from lal−/− MSCs, 
decreased proliferation of tumor cells was observed 
(Figure 4A), accompanied by reduced activation of 
ERK1/2, p38MAPK, and STAT3 oncogenic molecules 
in tumor cells (Figure 4B and 4C). This is in agreement 
with a previous report that MSC-secreted IL-6 facilitates 
cancer cell migration by persistent activation of MAPK, 
AKT and p38MAPK in breast cancer cells [21]. It is also 
agreed with our previous report that persistent activation 
of STAT3 induces adenocarcinoma in the lung, and STAT3 
serves as a biomarker for lung adenocarcinoma in humans 
[15, 16]. It is well known that the downstream metabolic 
derivatives of LAL serve as ligands for PPARγ, which 
controls expression of IL-6 [26]. We have shown that LAL 
downstream derivative 9-HODE treatment significantly 
reversed pathogenesis in lal−/− mice, including tumor 
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growth and tumor invasion [27, 28]. In addition, we 
have reported that metabolic enzyme LAL influences 
gene transcription of AKT, mTOR and STAT3 [14, 29], 
which control the secretion of MCP-1 and IL-10 and IL-6 
[30, 31]. 
MSCs possess immunosuppressive effects, which 
serves as another important mechanism through which 
MSCs promote tumor growth and progression. Djouad 
et al. reported that the immunosuppressive function of 
MSCs led to a higher incidence of melanoma formation in a 
Figure 4: MSC-CM stimulates activation of intracellular signaling molecules. (A) Stimulation of B16 melanoma cell 
proliferation by MSCs conditioned medium (CM). B16 melanoma cells (5 × 103) or LLCs (1 × 104) were seeded into 96-well plates, and 
then treated with CM from lal+/+ or lal−/− FVB/N or C57BL/6 MSCs. The cell number was counted at 72 h after CM treatment. (b) Activation 
of intracellular signaling molecules in B16 melanoma cells by MSCs CM. Two hours after CM treatment, B16 melanoma or LLC cells were 
harvested for flow cytometry analysis. lal−/− MSC-CM decreased phosphorylation of ERK, P38 and STAT3 in B16 melanoma and LLC 
cells. Statistical analysis of mean fluorescent intensity (MFI) by flow cytometry is shown. In the above experiments, data were expressed 
as mean ± SD; n = 3~4. *P < 0.05, **P < 0.01. 
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mouse model [17]. MSCs can directly inhibit proliferation 
and impair the function of a variety of immune cells, such 
as dendritic cells, T and B lymphocytes, and natural killer 
cells [6]. When MSCs and B16 melanoma cells were 
co-injected into wild type mice, there was no difference 
of CD4+ T cells between lal+/+ and lal−/− MSC-injected 
mice (Figure 5B). However, the percentage of CD8+ T 
cells was increased in the blood, lung and spleen of lal−/− 
MSC-injected mice compared with lal+/+ MSC-injected 
mice (Figure 5A). Interestingly, the percentage of T cell-
suppressing and tumor-promoting Ly6G+CD11b+ MDSCs 
was decreased in the blood and lung of lal−/− MSC-injected 
mice (Figure 5C). It is conceivable that the synergistic 
effect of increased CD8+ cytotoxic T cells and decreased 
MDSCs induced by lal−/− MSCs contributes to impaired 
tumor growth and metastasis. Conversely, lal−/− MDSCs 
facilitated MSC proliferation through MDSC-secreted 
cytokines and chemokines (Figure 7). 
Fibroblasts are an important component of stroma 
cells in the tumor microenvironment that support tumor 
growth. MSCs have the capacity to differentiate into TAFs 
within the tumor microenvironment, which is another 
potential mechanism underlying MSCs’ stimulation of 
tumor growth and progression. TAFs are characterized 
by the presence of several markers. After exposure to the 
tumor microenvironment, MSCs expressed TAF markers 
including Tn-C, α-SMA, desmin, and fibroblast marker 
Collagen I (Figure 6), indicating their differentiation 
Figure 5: lal−/− Mscs restored cd8+ T lymphocytes and decreased accumulation of Ly6G+cd11b+ Mdscs. B16 
melanoma cells (4 × 105) with or without MSCs (8 × 105) from lal+/+ or lal−/− FVB/N mice were intravenously co-injected into lal+/+ FVB/N 
mice. Seven days later, the blood, lung and spleen were harvested for flow cytometry analysis of the percentage of CD8+ T cells (A), CD4+ 
T cells (b), and Ly6G+CD11b+ MDSCs (c). Data were expressed as mean ± SD; n = 5. *P < 0.05, **P < 0.01. 
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Figure 6: LAL deficiency impaired MSC differentiation towards. (A) Real-time PCR analysis of mRNA expression levels 
of α-smooth muscle actin (α-SMA), tenascin-C (Tn-C), and collagen I in lal+/+ or lal−/− MSCs treated with control medium (Con) or 
conditioned medium (CM) from B16 melanoma cells. MSCs were seeded at a density of 1 × 105 cells/well into 6-well plates at day 0, and 
treated with 1 mL B16-CM or control medium. The medium was changed every 3 days. On day 14, MSCs were harvested for real-time 
PCR assay. The relative gene expression was normalized to GAPDH mRNA, and analysis was performed by the 2−ΔΔCT method. Data were 
expressed as mean ± SD; n = 4. **P < 0.01. (b) Representative IHC staining of the matrigel plug sections using antibodies against α-SMA 
and desmin. MSCs (2 × 105) from lal+/+ or lal−/− FVB/N mice were mixed with or without B16 melanoma cells (1 × 105) in matrigel, and the 
cell-matrigel-mixture was then injected subcutaneously into 3-month old lal+/+ FVB/N mice. Fourteen days later, the mice were sacrificed, 
and the plugs were harvested for IHC staining. Original magnification, ×400. 
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towards TAFs. lal−/− MSCs exhibited lower levels of these 
TAF markers than those of lal+/+ MSCs (Figure 6), serving 
as another mechanism to explain why LAL deficiency 
impairs MSCs’ tumor-stimulating ability.
In conclusion, LAL deficiency in MSCs results in the 
loss of tumor-promoting functions through regulating cell 
viability, secretion of paracrine factors, immunosuppressive 
function and fibroblastic differentiation. The LAL 
metabolic pathway can be a novel target to modulate the 
tumor-promoting functions of MSCs and reduce the risk of 
cancer progression and metastasis.
MAterIAls And Methods
Animals and cell lines 
Wild-type (lal+/+) and lal−/− mice of the FVB/N and 
C57BL/6 background were bred in house. All scientific 
protocols involving the use of animals have been approved 
by the Institutional Animal Care and Use Committee of 
Indiana University School of Medicine and followed 
guidelines established by the Panel on Euthanasia of 
the American Veterinary Medical Association. Animals 
were housed under Institutional Animal Care and Use 
Committee-approved conditions in a secured animal 
facility at Indiana University School of Medicine.
The murine B16 melanoma cell line and Lewis lung 
carcinoma (LLC) cell line (ATCC, Manassas, VA, USA) 
were cultured in DMEM supplemented with 10% FBS 
(Gibco, Grand Island, NY, USA).
Msc isolation 
MSCs were isolated from the bone marrow of 
femurs and tibias of 8-week-old FVB/N or C57BL/6 
mice and cultured in MSC basal medium supplemented 
with MSC stimulatory supplements (STEMCELL 
Technologies, Vancouver, Canada) as previously 
Figure 7: MDSCs partially restored decreased proliferation of lal−/− Mscs. (A) lal−/− MDSCs stimulated MSC proliferation in 
the co-culture study. MSCs were seeded at a density of 5 × 104 cells/well in 6-well plates, and lal+/+ or lal−/− MDSCs (2 × 106) were added 
to the well. The MSC number was counted at d1, d3, d5 and d7 afterwards. (b) lal−/− MDSCs stimulated MSC proliferation in the transwell 
study. MSCs (2 × 104) were seeded into the lower chamber of transwells plates, while MDSCs (1 × 106) were placed in the upper chamber. 
After 5 days, the MSC number was counted. (c) Neutralization of cytokines in MSC proliferation. lal+/+ MSCs (2 × 104) were seeded into 
the lower chamber of transwells, with MDSCs (1 × 106) placed in the upper chamber. MDSCs were treated with 10 μg/ml neutralizing 
antibody against IL-6, IL-1β, TNF-α, MCP-1 individually, in combination or with control immunoglobulin G at day 1 and day 3. After 
5 days, the number of MSCs was counted. In the above experiments, data were expressed as mean ± SD; n = 3~5. *P < 0.05, **P < 0.01. 
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described [32]. Cells were used at low passages P2 or 
P3 to avoid senescence-associated effects progressively 
acquired with passage [33]. 
Cell growth curve 
MSCs were seeded at a density of 5 × 104 cells per 
well in a 6 well plate on day 0. On day 1, 3, 5, and 7, MSCs 
were trypsinized and counted with a hemocytometer. The 
cell growth curve was then established by a graphical 
analysis of the data.
brdu incorporation 
BrdU incorporation was performed using the 
BrdU Flow Kit (BD Biosciences, San Jose, CA, USA) 
as we previously described [11]. Briefly, BrdU was 
added to MSCs at a final concentration of 10 μmol/L. 
One hour later, cells were collected and fixed. After 
permeabilization, cells were incubated with DNase 
I at 37°C for 1 h, followed by labeling with anti-BrdU 
antibody for 20 min at room temperature. Cells were then 
analyzed by flow cytometry.
real-time rt-Pcr
Total RNAs from MSCs were purified using the 
Qiagen total RNA purification kit (Qiagen, Valencia, 
CA, USA). Quantitative (q)RT-PCR was performed as 
described previously [34]. Analysis was performed by 
the 2−ΔΔCT method. Primers of mIL-6, mMCP-1, mIL-10, 
mCCNA2, mCCNB1, mCCNB2, mCCNE2, mCDK1, 
mCDK2, mBAX, mBAK, mBID, mAPAF1, mCaspase 3, 
6, 7, 8 and 9, α-SMA, Tn-C, collagen I A1, and GAPDH 
for real-time PCR were described previously [12, 34–36]. 
Annexin V staining 
Dual staining with FITC–annexin V and propidium 
iodide (PI) was performed to detect cells undergoing 
apoptosis using an annexin V–FITC kit (BD Biosciences) 
as we described previously [12]. MSCs were harvested, 
and resuspended in annexin V-binding buffer containing 
FITC-conjugated annexin V. PI was then added into cells 
and incubated on ice for 10 min. Nonspecific binding was 
blocked by pre-incubating cells with rat IgG (10 mg/mL) 
and anti-FcII/III. Cells were analyzed on a LSRII machine 
(Becton Dickinson, Franklin Lakes, NJ, USA) within 1 h. 
Viable cells were defined by FITC– and PI– population. 
Early apoptotic cells were defined by FITC+ and PI– 
population. 
Caspase 3 activity assay
Caspase 3 activity in MSCs was detected using 
Caspase-3 Assay Kit according to the manufacturer’s 
instructions (BD Biosciences). Briefly, cells were lysed in 
cold cell lysis buffer for 30 min on ice. The cell lysate was 
then incubated with caspase-3 substrate Ac-DEVD-AMC 
at 37°C for 1 h. The caspase-3 activity was quantified 
using a spectrofluorometer with excitation at 380 nm and 
emission at 440 nm.
Mouse tumor growth and metastasis model
The tumor growth and metastasis model have 
been described recently [18]. MSCs and B16 melanoma 
cells were collected separately. A pilot study has been 
performed to determine the best ratio between MSCs and 
B16 melanoma cells. To test the tumor growth potential, 
6 × 105 MSCs isolated from FVB/N or C57BL/6 
mice and 2 × 105 B16 melanoma cells were mixed, 
centrifuged and re-suspended in 100 μL PBS, and then 
injected subcutaneously into the flank region of 3-month 
old recipient lal+/+ mice in the FVB/N or C57BL/6 
background. Tumor volume (length × width2 × π/6) was 
monitored every week for 4 weeks. To test the metastasis 
potential, 8 × 105 MSCs and 4 × 105 B16 melanoma cells 
were mixed, centrifuged and re-suspended in 200 µL 
PBS, and then injected intravenously into 3-month old 
lal+/+ FVB/N or C57BL/6 mice. Two weeks after the 
injection, the mice were sacrificed and the lungs were 
inflated with 4% paraformaldehyde for examination of 
metastasis.
Isolation of bone marrow-derived MDSCs
MDSCs were isolated as we previously described 
[18, 29]. As previously published, almost all lal−/− 
MDSCs are Ly6G+Ly6C+, and almost all lal−/− MDSCs 
are CD11b+Ly6G+ cells [18, 29]. Therefore, to simplify 
the isolation procedure, Ly6G antibody-coupled magnetic 
beads were used and sufficiently isolate lal−/− MDSCs 
from the lal−/− bone marrow, and the equivalent control 
from the wild type bone marrow [11, 37]. Briefly, bone 
marrow cells were isolated from the femurs and tibias of 
mice. Cells were first incubated with biotin-conjugated 
anti-Ly6G antibody at 4°C for 15 min. After washed with 
PBS, cells were incubated with anti-biotin microbeads 
at 4°C for another 15 min. Subsequently, cells were 
subjected to magnetic bead sorting according to the 
manufacturer’s instructions (Miltenyi Biotec., Auburn, 
CA, USA). 
In vitro co-culture of Mscs and Mdscs
A pilot study was performed to determine the best 
ratio between MSCs and MDSCs. MSCs (5 × 104) and 
MDSCs (2 × 106) were mixed, and seeded into a well of 
6-well plates at day 0. At day 1, 3, 5, and 7, unattached 
MDSCs were removed by washing with PBS, and the 
number of attached MSCs was counted. Morphologically, 




For measurement of intracellular signaling 
molecules in B16 melanoma and LLC cells, 2 h after 
MSC-conditioned medium (CM) treatment, cells were 
harvested, fixed and permeabilized using BD Cytofix/
Cytoperm Fixation/Permeabilization Kit (BD Biosciences) 
according to the manufacturer’s instructions, and then 
incubated with Alexa Fluor 647-conjugated anti-phospho-
Akt antibody, anti-phospho-P44/42 (Erk1/2) antibody, 
anti-phospho-NF-κB antibody, anti-phospho-P38 
antibody, and anti-phospho-Stat3 antibody (Cell Signaling 
Technology, Beverly, MA, USA) at 4°C overnight. In 
the following day, cells were washed and ready for flow 
cytometry analysis. 
For immune cell profile analysis in mice that were 
co-injected with MSCs and B16 melanoma cells, single 
cells from the blood, spleen and lung were harvested as 
previously described [12, 38]. Cells were labeled with anti-
Ly6G, anti-CD11b, anti-CD4, and anti-CD8 cell surface 
antibodies (eBioscience, San Diego, CA, USA) at 4°C for 
15 min, and then washed for flow cytometry analysis. 
For analysis of MSC existence in the metastatic 
sites, 1 × 106 CMFDA-labeled lal+/+ or lal−/− FVB/N MSCs 
were intravenously co-injected with B16 melanoma cells 
(5 × 105) into FVB/N lal+/+ mice. Sixteen hours later, 
the mice were sacrificed, and single cells from the lung, 
spleen and blood were harvested as previously described 
for flow cytometry analysis of MSC existence [12, 38]. 
For flow cytometry analysis, ≥10,000 cells were acquired 
and scored using a LSRII machine (BD Biosciences). Data 
were processed using the CellQuest software program (BD 
Biosciences).
Cytokine measurement by ELISA
MSCs were seeded at a density of 5 × 105 cells per 
well in 6-well plates. Three days later, the conditioned 
medium was harvested. The expression levels of IL-6, IL-
10, and monocyte chemoattractant protein (MCP) -1 (BD 
Biosciences) in the conditioned medium were measured 
using ELISA kits according to the manufacturer’s 
instructions.
Msc differentiation towards tAFs
For in vitro differentiation, lal+/+ or lal−/− MSCs were 
treated with control medium or conditioned medium (CM) 
from B16 melanoma cells for 14 days. B16 melanoma 
cells were grown in DMEM +10% FBS culture medium 
and CM was harvested after 24 h. CM was centrifuged and 
supernatant was collected. MSCs were seeded at a density 
of 1 × 105 cells/well of 6-well plates, and treated with 
1 mL B16-CM or DMEM +10% FBS control medium at 
day 0. The medium was changed every 3 days. On day 14, 
MSCs were harvested for real-time PCR assay of α-SMA, 
Tn-C and collagen I. 
For in vivo differentiation, 2 × 105 MSCs from lal+/+ 
or lal−/− FVB/N mice were mixed with or without B16 
melanoma cells (1 × 105) in matrigel, and the cell-matrigel-
mixture was then injected subcutaneously into 3-month 
old lal+/+ FVB/N mice. Fourteen days later, the mice were 
sacrificed, and the plugs were harvested for IHC staining 
against TAF marker α-SMA and desmin by Pathology 
Laboratory of Indiana University School of Medicine. 
Transwell assay
To observe the effect of MDSCs-secreted cytokines 
on MSC proliferation, transwell assay was performed with 
0.4-µm-pore 6.5-mm diameter Transwell plates (Corning, 
Corning, NY, USA) to separate MDSCs and MSCs. One 
million lal+/+ or lal−/− MDSCs in 200 µL media were 
seeded into the upper chamber of the plates, while 2 × 104 
MSCs in 500 µL media were placed in the lower chamber. 
For the neutralization study, MDSCs were treated with 10 
μg/mL neutralizing antibody against IL-6, IL-1β, TNF-α, 
MCP-1 or control IgG. After 5 days’ culture, the transwells 
were removed, and the number of MSCs in the lower 
chamber was counted. 
statistics 
Data were expressed as mean ± SD. Differences 
between two treatment groups were compared by Student’s 
t-test. When more than two groups were compared, one-
way ANOVA with post-hoc Newman-Keul’s multiple 
comparison test was used. Results were considered 
statistically significant when P < 0.05. All analyses were 
performed with GraphPad Prism 5.0 (GraphPad, San 
Diego, CA, USA).
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